Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine
Hepatitis E virus still poses a great threat to public health worldwide. To date, Hecolin® is the only licensed HEV vaccine in China. Total anti-HEV antibody has been used to reflect vaccine induced immune response in clinical trials for the lack of robust HEV neutralizing antibody detection methods...
Saved in:
Main Authors: | Xing Wu (Author), Pan Chen (Author), Huijuan Lin (Author), Yao Su (Author), Xiaotian Hao (Author), Yufeng Cao (Author), Li Li (Author), Fengcai Zhu (Author), Zhenglun Liang (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2017-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Heterologous Prime-boost COVID-19 Vaccination
by: Vishal R. Tandon, et al.
Published: (2021) -
Novel prime-boost vaccine strategies against HIV-1
by: Jean-Louis Excler, et al.
Published: (2019) -
Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
by: Om Prakash Choudhary, et al.
Published: (2021) -
Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
by: Tesfaye Gelanew, et al.
Published: (2023) -
Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis
by: Mathilde Bahuaud, et al.
Published: (2018)